Draft: Glossary of Quality Terms

Notice to the reader:

The online consultation is now closed. The final glossary is available now. Comments and suggestions received from the consultation on the draft version of the guidance were reviewed and considered in the finalization of this document.

This guidance document is being distributed for comment purposes only.

Draft Date - 2016/08/31

This glossary only includes terms used in the Guidance Document: Quality (Chemistry and Manufacturing): New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs) which are not defined in International Council for Harmonisation (ICH) guidance documents or other Health Canada Documents

For additional definitions of terms used in quality documents, refer to the following documents:


Bridging study:
A bridging study is defined as a supplemental study performed to provide bioequivalence, pharmacodynamic or clinical data to support that significant changes in the formulation or manufacturing of a drug product result in an equivalent product to the product used for pivotal clinical trials. Such studies usually involve bioequivalence studies.
Drug product intermediate:
A material that is the result of a drug substance having undergone at least one processing step in the presence of any other substance(s) (used in the manufacture of the drug product whether it appears in the finished dosage form or not) which must undergo further processing step(s) to become the finished dosage form.

That first processing step of the drug substance in the presence of any other substance(s) would be considered a drug product manufacturing (fabrication) activity, subject to Part C, Division 2 of the Food and Drug Regulations, and would define the date from which the expiry date for the drug product would be established.
This is a term defined in GUI-001, but is considered synonymous with the ICH Q7 term “manufacture” in the guidance document : Quality (Chemistry and Manufacturing): New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs).
Key Intermediate:
an intermediate in which an essential molecular characteristic(s), usually involving the proper stereochemical configuration required for structure/activity (pharmacological and/or physiological activity of the drug substance), is first introduced into the structure (for example [e.g.], introduction of a chiral centre, as exemplified by the Corey aldehyde in prostaglandin syntheses, or the production of one geometric isomer in preference to another).
Mass Balance:
The process of adding together the assay value and levels of degradation products to see how closely these add up to 100% of the initial value, with due consideration of the margin of analytical error.
Semi-synthetic drug product:
A drug product containing one or more semi-synthetic drug substance(s), or a drug product containing both synthetic (or semi-synthetic) and non-synthetic/non-semi-synthetic drug substances (e.g. a drug product containing both a synthetic drug substance and a biological drug substance).
Semi-synthetic drug substance:
A semi-synthetic drug substance is one in which the structural constituents have been introduced by a combination of chemical synthesis and elements of biological origin (e.g., obtained from fermentation or by extraction from botanical material). A synthesis step involves cleavage and formation of covalent bonds.
Small Scale Batch:
A small scale batch is considered less than 100 000 units for solid oral dosage forms or less than 10% of commercial scale batch size. The batch is manufactured in a manner that is considered representative of the proposed commercial scale process.

Document Change Log

Version: Glossary of Quality Terms
Date: 2016/08/31

Replaces: Not Applicable. New Guidance

Page details

Date modified: